CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Essential oilsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug2443 Tap water Wiki 1.00
drug1883 Povidone-Iodine Wiki 0.50
drug1695 Ontamalimab Wiki 0.50
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D014456 Ulcer NIH 0.41
D003092 Colitis NIH 0.41
D003093 Colitis, Ulcerative NIH 0.41

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0002583 Colitis HPO 0.41
HP:0100279 Ulcerative colitis HPO 0.41

There is one clinical trial.

Clinical Trials

1 A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients

The purpose of this study is to assess the ability of regular gargling to eliminate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the throat and nasopharynx. This 4 arms interventional study compares the effect of gargling using povidone-iodine, essential oils- based, tap water with control (no intervention) among Stage 1 coronavirus disease-2019 (COVID-19) patients. Findings from this study will provide new insight into the importance of gargling in the treatment and prevention of COVID-19.

NCT04410159 COVID-19 Drug: Povidone-Iodine Drug: Essential oils Other: Tap water

Primary Outcomes

Description: Viral clearance is defined as two negative RT-PCR (of swabs from oropharynx and nasopharynx) results at least 24 hours apart

Measure: Number of Participants With Early Viral Clearance

Time: Day 6

Secondary Outcomes

Description: RT-PCR (swabs from oropharynx and nasopharynx) taken at day 12

Measure: Number of Participants With Negative RT-PCR Results

Time: Day 12

Description: Presence of signs and symptoms of more severe COVID19 Based symptoms diary and clinical evaluation

Measure: Number of Patients That Progress to More Severe Disease

Time: Day 12

Description: abnormal chest x-ray or CT scan

Measure: Number of Patients With Abnormal Radiological Findings

Time: Day 0-14

Description: Abnormal absolute lymphocytic count Abnormal C-reactive protein

Measure: Number of Patients With Abnormal Laboratory Findings

Time: Day 0-14

No related HPO nodes (Using clinical trials)